FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135420706> ?p ?o ?g. }

• W3135420706 endingPage "1426" @default.
• W3135420706 startingPage "1426" @default.
• W3135420706 abstract "<h3>Importance</h3> Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. <h3>Objective</h3> To determine whether ivermectin is an efficacious treatment for mild COVID-19. <h3>Design, Setting, and Participants</h3> Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state’s health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020. <h3>Intervention</h3> Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200). <h3>Main Outcomes and Measures</h3> Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected. <h3>Results</h3> Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32];<i>P</i> = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group). <h3>Conclusion and Relevance</h3> Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT04405843" @default.
• W3135420706 created "2021-03-15" @default.
• W3135420706 creator A5002609983 @default.
• W3135420706 creator A5003386151 @default.
• W3135420706 creator A5005658261 @default.
• W3135420706 creator A5011251700 @default.
• W3135420706 creator A5014346300 @default.
• W3135420706 creator A5015136181 @default.
• W3135420706 creator A5019436616 @default.
• W3135420706 creator A5023944963 @default.
• W3135420706 creator A5035501216 @default.
• W3135420706 creator A5035879185 @default.
• W3135420706 creator A5037981232 @default.
• W3135420706 creator A5040987821 @default.
• W3135420706 creator A5043020214 @default.
• W3135420706 creator A5045660011 @default.
• W3135420706 creator A5052621568 @default.
• W3135420706 creator A5056030770 @default.
• W3135420706 creator A5073464882 @default.
• W3135420706 creator A5080177331 @default.
• W3135420706 creator A5083606117 @default.
• W3135420706 date "2021-04-13" @default.
• W3135420706 modified "2023-10-17" @default.
• W3135420706 title "Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19" @default.
• W3135420706 cites W1965936780 @default.
• W3135420706 cites W1973722820 @default.
• W3135420706 cites W1991249533 @default.
• W3135420706 cites W2165157662 @default.
• W3135420706 cites W2794814824 @default.
• W3135420706 cites W3008028633 @default.
• W3135420706 cites W3009301311 @default.
• W3135420706 cites W3011976215 @default.
• W3135420706 cites W3012379316 @default.
• W3135420706 cites W3014962324 @default.
• W3135420706 cites W3016868609 @default.
• W3135420706 cites W3026052479 @default.
• W3135420706 cites W3027630905 @default.
• W3135420706 cites W3033658063 @default.
• W3135420706 cites W3036816996 @default.
• W3135420706 cites W3049675844 @default.
• W3135420706 cites W3080718665 @default.
• W3135420706 cites W3096545806 @default.
• W3135420706 cites W3097814025 @default.
• W3135420706 cites W3110529717 @default.
• W3135420706 cites W3110602237 @default.
• W3135420706 cites W4238803207 @default.
• W3135420706 cites W4242313457 @default.
• W3135420706 doi "https://doi.org/10.1001/jama.2021.3071" @default.
• W3135420706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7934083" @default.
• W3135420706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33662102" @default.
• W3135420706 hasPublicationYear "2021" @default.
• W3135420706 type Work @default.
• W3135420706 sameAs 3135420706 @default.
• W3135420706 citedByCount "267" @default.
• W3135420706 countsByYear W31354207062020 @default.
• W3135420706 countsByYear W31354207062021 @default.
• W3135420706 countsByYear W31354207062022 @default.
• W3135420706 countsByYear W31354207062023 @default.
• W3135420706 crossrefType "journal-article" @default.
• W3135420706 hasAuthorship W3135420706A5002609983 @default.
• W3135420706 hasAuthorship W3135420706A5003386151 @default.
• W3135420706 hasAuthorship W3135420706A5005658261 @default.
• W3135420706 hasAuthorship W3135420706A5011251700 @default.
• W3135420706 hasAuthorship W3135420706A5014346300 @default.
• W3135420706 hasAuthorship W3135420706A5015136181 @default.
• W3135420706 hasAuthorship W3135420706A5019436616 @default.
• W3135420706 hasAuthorship W3135420706A5023944963 @default.
• W3135420706 hasAuthorship W3135420706A5035501216 @default.
• W3135420706 hasAuthorship W3135420706A5035879185 @default.
• W3135420706 hasAuthorship W3135420706A5037981232 @default.
• W3135420706 hasAuthorship W3135420706A5040987821 @default.
• W3135420706 hasAuthorship W3135420706A5043020214 @default.
• W3135420706 hasAuthorship W3135420706A5045660011 @default.
• W3135420706 hasAuthorship W3135420706A5052621568 @default.
• W3135420706 hasAuthorship W3135420706A5056030770 @default.
• W3135420706 hasAuthorship W3135420706A5073464882 @default.
• W3135420706 hasAuthorship W3135420706A5080177331 @default.
• W3135420706 hasAuthorship W3135420706A5083606117 @default.
• W3135420706 hasBestOaLocation W31354207061 @default.
• W3135420706 hasConcept C119060515 @default.
• W3135420706 hasConcept C126322002 @default.
• W3135420706 hasConcept C142724271 @default.
• W3135420706 hasConcept C168563851 @default.
• W3135420706 hasConcept C187212893 @default.
• W3135420706 hasConcept C197934379 @default.
• W3135420706 hasConcept C204787440 @default.
• W3135420706 hasConcept C207103383 @default.
• W3135420706 hasConcept C27081682 @default.
• W3135420706 hasConcept C2777499811 @default.
• W3135420706 hasConcept C2779134260 @default.
• W3135420706 hasConcept C2908647359 @default.
• W3135420706 hasConcept C3008058167 @default.
• W3135420706 hasConcept C42972112 @default.
• W3135420706 hasConcept C44249647 @default.
• W3135420706 hasConcept C524204448 @default.
• W3135420706 hasConcept C535046627 @default.
• W3135420706 hasConcept C71924100 @default.
• W3135420706 hasConcept C99454951 @default.

• next